News Related to Fallopian Tube

Related coverage linked through entity extraction aliases.

FDA Approves Lifyorli Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer

Mar 26, 2026

The FDA has approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer based on trial data showing improved survival. Separately, the agency granted Breakthrough Therapy designation to Lilly's sofetabart mipitecan for the same condition, expediting development of the antibody-drug conjugate.

Barclays Initiates Merck Coverage with Overweight Rating on 2026 Drug Pipeline

Feb 20, 2026

Barclays initiated coverage on Merck with an overweight rating and $140 price target, citing expected product launches including enlicitide and pivotal trial readouts for tulisokibart in 2026.